SCHEMBL27434847

SCHEMBL27434847

COC(=O)c1c(OC)c(Cl)cc2c1OCCN2C(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
TAS1R2 Q8TE23 1/20 0.36
MAPT P10636 1/20 0.35
ENPP2 Q13822 1/20 0.34
DRD3 P35462 7/20 0.34
DRD2 P14416 5/20 0.34
DRD1 P21728 4/20 0.34
DRD4 P21917 4/20 0.34
DRD5 P21918 4/20 0.34
KDM4E B2RXH2 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34
HSD17B10 Q99714 1/20 0.34
NOTUM Q6P988 1/20 0.33
CDK6 Q00534 2/20 0.33
CDK4 P11802 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27434865 0.89 KDM4E (0.40) TAS1R3TAS1R1TAS1R2MAPTDRD3
SCHEMBL30954071 0.89 KDM4E (0.40) TAS1R3TAS1R1TAS1R2MAPTDRD3
SCHEMBL27434669 0.83 MAPT (0.39) TAS1R3TAS1R1TAS1R2MAPTENPP2
SCHEMBL27435327 0.81 DRD2 (0.40) DRD3DRD2DRD1DRD4DRD5
SCHEMBL27432939 0.80 MAPT (0.38) TAS1R3TAS1R1TAS1R2MAPTDRD3
SCHEMBL27435508 0.77 DRD3 (0.41) MAPTDRD3DRD2KMT2A
SCHEMBL27435244 0.76 TP53 (0.43) MAPTKDM4ECYP1A2CYP2C19KMT2A
SCHEMBL27435492 0.76 CPT2 (0.32) TAS1R3TAS1R1TAS1R2MAPTENPP2
SCHEMBL27435364 0.75 KCNA3 (0.42) DRD3DRD2DRD4KDM4E
SCHEMBL30954135 0.74 POLB (0.44) MAPTKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630412-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP disclosed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed